Open AccessAlmotriptan 12.5 mg in menstrually related migraine: A randomized, double-blind, placebo-controlled study
Author(s) -
Gianni Allais,
Gennaro Bussone,
Giovanni D’Andrea,
F. Moschiano,
Florindo d’Onofrio,
Fabio Valguarnera,
Gian Camillo Manzoni,
Licia Grazzi,
Rita Allais,
Chiara Benedetto,
Giancarlo Acuto
Publication year - 2010
Publication title -
cephalalgia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.57
H-Index - 125
eISSN - 1468-2982
pISSN - 0333-1024
DOI - 10.1177/0333102410378048
Subject(s) - medicine , migraine , placebo , triptans , adverse effect , anesthesia , nausea , sumatriptan , randomized controlled trial , pathology , alternative medicine , agonist , receptor
Menstrually related migraine (MRM) affects more than half of female migraineurs. Because such migraines are often predictable, they provide a suitable target for treatment in the mild pain phase. The present study was designed to provide prospective data on the efficacy of almotriptan for treatment of MRM.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom